Navigation Links
Clinical trial to test whether vaccine can effectively treat melanoma
Date:4/6/2010

CHICAGO Rush University Medical Center is leading a nationwide Phase III clinical trial to determine whether a promising vaccine for advanced melanoma can effectively treat the deadly skin cancer.

An earlier Phase II trial of the experimental drug involving 50 patients with metastatic melanoma had stunning results. Eight patients recovered completely and four partially responded to the vaccine.

"Very few treatment options exist for patients with advanced melanoma, none of them satisfactory, which is why oncologists are so excited about the results we found in our Phase II study," said Dr. Howard Kaufman, associate dean of Rush Medical College and director of the Rush Cancer Program. Kaufman is leading the Phase III study.

Melanoma is a rare but deadly disease whose incidence is rising. According to the National Cancer Institute, there were 68,700 new cases of melanoma in 2009, and more than 8,500 deaths. The cancer typically begins in a mole, but can also lodge in other pigmented tissues, such as in the eye or in the intestines. If caught early, when the disease is superficial, the lesions can easily be removed surgically. But if it advances, the prognosis is poor. Median survival is six months to two years.

The vaccine being tested is called OncoVEX, initially developed to combat herpes virus. Researchers discovered accidentally that the vaccine attacked cancerous tissue when it was inadvertently placed in a Petri dish of tumor cells. The vaccine includes an oncolytic virus, a reprogrammed virus that has been converted into a cancer-fighting agent that attacks tumor cells while leaving healthy cells undamaged. OncoVEX also carries biological agents that boost the immune response to melanoma.

The vaccine is injected directly into lesions that can be felt or seen, with or without ultrasound. The procedure is generally done in a physician's office.

The earlier Phase II trial, an initial test o
'/>"/>

Contact: Sharon Butler
Sharon_Butler@rush.edu
312-942-7816
Rush University Medical Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. The CPM Resource Center launches Web-based clinical practice guidelines
2. Clinical benefit of multiple sclerosis drug discovered at Rush University Medical Center
3. Childrens Hospital Bostons Pain Treatment Service is named Clinical Center of Excellence
4. Almac to Improve Label Approval Process in Clinical Trials
5. Targeted agent blocked growth of deadly brain cancer in preclinical studies
6. New clinical prediction index to help patients considering kidney transplant
7. Kineta Awarded NIH Grant to Complete Preclinical Studies on Type 1 Diabetes / Multiple Sclerosis Drug Candidate
8. Childhood cancer patients enrolled in clinical trials need clearer communication about their role
9. Medical schools partner to tackle barriers to minority participation in cancer clinical trials
10. Carefx to Provide Clinical Workflow Solutions for Military Health System
11. The Indiana Clinical and Translational Science Institute (CTSI) Licenses GeneGos Eureka and MetaCore Platforms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... OH (PRWEB) December 22, 2014 Explorys, ... three additions to its leadership team: Greg Yarrington as ... of Engineering, and Patrick Wells as Vice President of ... to add 80 new jobs in 2015 to support ... expansion of its platform-as-a-service offerings, and growth of its ...
(Date:12/22/2014)... CA (PRWEB) December 22, 2014 ... now offering consultations for sleep apnea. Drowsy drivers are ... than drivers who are well-rested, and some experts believe ... the roads as intoxicated drivers. Unfortunately, millions of Americans ... the American Academy of Sleep Medicine, about 18 million ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 Christmas is days ... has a fast and easy solution that will please: the ... can be purchased from from $25 up to $350," says ... 100% customer satisfaction and a wide array of skin care ... fees and no expiration dates. , Gift delivery past ...
(Date:12/22/2014)... Washington, DC (PRWEB) December 22, 2014 ... Nursing Leadership Conference, next month in San ... strategies to address dynamics that often stand in ... authority, and competition. , This premier faculty ... Center for Transformational Leadership, whose mission is to ...
(Date:12/21/2014)... (PRWEB) December 22, 2014 BellasDress.com offers ... more for women. Today, it announces its BellasDress ... products at its online store. , BellasDress is a ... benefits to its fans through a series of promotions. ... for every customer. , “We are proud of ...
Breaking Medicine News(10 mins):Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 2Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 3Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2Health News:2015 NLN Leadership Conference February 5-7 San Antonio 2Health News:2015 NLN Leadership Conference February 5-7 San Antonio 3Health News:BellasDress.com Announces its BellasDress Christmas Sale 2
... development by a team of researchers at the University of ... medical procedures. , The system works by using a Web-based ... children from the procedures that cause the pain. The distractions ... watching a video, talking, or playing a game. , The ...
... is proud to announce,that President and CEO Humberto ... Jury President for North America. Jury members for ... their,achievements in the business, non-profit and academic fields, ... The awards, an annual distinction supporting innovative woman-led,business ...
... to Brooke Army Medical Center, RESTON, Va., ... ), an information technology and network solutions (IT),company, ... competitive task order under,the US Army,s HRsolutions Indefinite ... and Support to provide,services to Brooke Army Medical ...
... Illinois at Chicago has been named one of 10 ... consumers and clinicians make critical treatment decisions about therapeutic ... of the Agency for Healthcare Research and Quality,s Center ... It will design and test systems to optimize drug ...
... Oct. 16 (HealthDay News) -- A new gene associated with ... Dmp1 gene may help improve understanding of what ... , The Wake Forest University School of Medicine researchers analyzed ... the Dmp1 gene -- which normally works to ...
... 16 Starpharma,Holdings Ltd (ASX: SPL, Pink Sheets: ... SSL International plc (LSE: SSL), owner of Durex(R), ... which a commercial licence will be negotiated,sets out ... coating.,Undisclosed fees are payable to Starpharma under the ...
Cached Medicine News:Health News:UI researchers seek to ease children's pain during medical procedures 2Health News:UI researchers seek to ease children's pain during medical procedures 3Health News:Galderma Associates Itself to Cartier's Women's Initiative Awards to Recognize Female Entrepreneurs From Around the Globe 2Health News:Galderma Associates Itself to Cartier's Women's Initiative Awards to Recognize Female Entrepreneurs From Around the Globe 3Health News:SI International Awarded $4 Million Army HRsolutions Task Order 2Health News:SI International Awarded $4 Million Army HRsolutions Task Order 3Health News:New UIC center to study drug choices, safety 2Health News:Researchers ID New Gene Linked to Lung Cancer 2Health News:Starpharma and Durex Sign Co-Development Agreement for VivaGel(R)-Coated Condoms 2
(Date:12/22/2014)... 2014  Eiger BioPharmaceuticals Incorporated announced the positive ... in patients with chronic hepatitis delta virus (HDV) ... Institutes of Health (NIH) Clinical Center in ... placebo-controlled, dose ascending study evaluated two doses of ... twice daily for 28 days.  "This proof-of-concept study ...
(Date:12/19/2014)... the Friday, December 19 edition of USA ... (HIT) features Konica Minolta, the company announced today. The supplement will ... healthcare organizations. In addition to the print section ... New York , Chicago , ... Minneapolis and San Francisco , ...
(Date:12/19/2014)... Dec. 19, 2014  Advanced Medical Isotope Corporation ... engaged primarily in the development of brachytherapy devices ... today announced that a Life Sciences Discovery Fund ... for which AMIC is the commercialization partner.  The ... for the proposal titled "Optimized Injectable Radiogels for ...
Breaking Medicine Technology:Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3USA Today Supplement Featuring Konica Minolta Focuses on Impact of Healthcare IT 2Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 2Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 3
... 2007 /PRNewswire/ - Cytochroma Inc.,announced today positive data ... The initial top-line results from this trial,showed that ... are expected in August 2007. , The recently ... randomized study of CTA018 Injection,administered to 20 healthy ...
... PRINCETON, N.J.--(BUSINESS WIRE)--Jun 28, 2007 - Cytogen,Corporation ... Phase 1,dose escalation study evaluating QUADRAMET(R) (samarium ... Pharmaceuticals, Inc.) in patients with relapsed,multiple myeloma. ... in a,poster titled, "Phase 1 Trial of ...
Cached Medicine Technology:Cytochroma Reports Positive Phase I Clinical Data for CTA018,Injection 2Cytochroma Reports Positive Phase I Clinical Data for CTA018,Injection 3Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 2Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 3Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 4Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 5Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 6Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 7Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 8
Concave inner surface to conform to the globe. Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Wide scleral bed. Outside diameter 30.2 mm....
...
...
...
Medicine Products: